Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 9/20 | 0.40 |
| ▸ | MMP3 | P08254 | 7/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PGD | P52209 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 3/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | MMP7 | P09237 | 1/20 | 0.33 |
| ▸ | Q9HBH1 | 1/20 | 0.33 | |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25634004 | 1.00 | MAPT (0.41) | MAPTMMP2MMP3SLC22A6SMN1; SMN2 | |
| SCHEMBL19776046 | 1.00 | MAPT (0.41) | MAPTMMP2MMP3SLC22A6SMN1; SMN2 | |
| SCHEMBL20997017 | 0.84 | MAPT (0.36) | MAPTMMP2MMP3HDAC2ECE1 | |
| SCHEMBL19776924 | 0.84 | MAPT (0.39) | MAPTMMP2MMP3SLC22A6SMN1; SMN2 | |
| SCHEMBL20349752 | 0.83 | ALDH1A1 (0.36) | MAPTMMP2MMP3HDAC2 | |
| SCHEMBL13082195 | 0.82 | EPHX1 (0.35) | MAPTMMP2MMP3MMP1MMP7 | |
| SCHEMBL20806869 | 0.82 | MAPT (0.38) | MAPTMMP2MMP3SLC22A6SMN1; SMN2 | |
| SCHEMBL22336123 | 0.81 | MAPT (0.41) | MAPTMMP2MMP3HDAC2 | |
| SCHEMBL26342705 | 0.80 | MAPT (0.39) | MAPTMMP2MMP3SLC22A6 | |
| SCHEMBL24735487 | 0.80 | ALDH1A1 (0.44) | MAPTMMP2MMP3MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066141-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066141-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240018159-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11826432-B2 | Linkers, conjugates and applications thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-28 | — | — | US | disclosed |
| US-11826432-B2 | Linkers, conjugates and applications thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-28 | — | — | US | disclosed |
| US-20230372511-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-11814394-B2 | Exatecan derivatives, linker-payloads, and conjugates and thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | NOVARTIS AG (CH) | 2023-10-10 | — | — | US | disclosed |
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | NOVARTIS AG (CH) | 2023-10-10 | — | — | US | disclosed |
| US-20230271977-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271977-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | XPOT, ENGASE, ENTPD8 | MAPT 349/4885MMP2 1356/4885MMP3 1699/4885 |
| US-20230372511-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | FCGR1A, FCGR2A, TLR3 | MAPT 3914/4885MMP2 3668/4885MMP3 3568/4885 |
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | GNA15, GNA11, EEA1 | MAPT 3687/4885MMP2 4253/4885MMP3 4147/4885 |
| US-11814394-B2 | Exatecan derivatives, linker-payloads, and conjugates and thereof | XPOT, ENGASE, ENTPD8 | MAPT 349/4885MMP2 1356/4885MMP3 1699/4885 |
| US-11826432-B2 | Linkers, conjugates and applications thereof | CD44, EPCAM, MSN | MAPT 1140/4885MMP2 687/4885MMP3 1460/4885 |
| US-20240066141-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | CD44, EPCAM, MSN | MAPT 1140/4885MMP2 687/4885MMP3 1460/4885 |
| US-20180015176-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | TNFSF11, TNFRSF9, CD40 | MAPT 1120/4885MMP2 1914/4885MMP3 1333/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | MAPT 3191/4885MMP2 475/4885MMP3 1325/4885 |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | KIF5B, KIF23, KIF2C | MAPT 127/4885MMP2 2941/4885MMP3 1497/4885 |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | MAPT 38/4885MMP2 2320/4885MMP3 1995/4885 |
| US-20240018159-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | XPOT, ENGASE, ENTPD8 | MAPT 349/4885MMP2 1356/4885MMP3 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.